Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Transcatheter pulmonary valve replacement (TPVR) with Medtronic’s self-expanding Harmony valve is both safe and effective after more than a year, according to new real-world data published in the Journal of the American College of Cardiology.[1]

TPVR with self-expanding Harmony valve associated with ‘excellent’ real-world outcomes

Transcatheter pulmonary valve replacement is still linked to certain risks, researchers noted, but new data confirm it is a safe, effective treatment option for patients with severe PR. 

Osso VR, a San Francisco-based virtual reality (VR) company, has developed a new VR training simulation focused on left atrial appendage occlusion (LAAO) procedures. The simulation is designed to offer clinicians a new way to practice LAAO procedures in a “repeatable, risk-free virtual environment.”

Cardiologist-approved VR for interventional procedures headed to ACC.24

San Francisco-based Osso VR and the American College of Cardiology have collaborated on advanced LAAO simulations. The two groups first started working together back in 2022. 

Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its TriClip transcatheter edge-to-edge repair (TEER) system designed to treat tricuspid regurgitation (TR).

FDA approves Abbott’s TriClip TEER device for tricuspid regurgitation

Less than two months after an FDA advisory panel voted in favor of approval, the transcatheter edge-to-edge repair system can now be sold and marketed in the United States.

Newsweek ranked the 50 best heart hospitals in the world

Moderate prosthesis-patient mismatch after SAVR linked to worse long-term outcomes

The long-term impact of moderate PPM remains unclear. To learn more, researchers explored dozens of different studies from over the years, sharing their work in the Journal of the American Heart Association.

New risk score helps cardiologists predict when TAVR patients may require dialysis

Patients who need renal replacement therapy after TAVR are much less likely to survive. Researchers hope their new risk score can help care teams prepare ahead of time for this rare, but potentially fatal complication. 

Medtronic has received U.S. Food and Drug Administration (FDA) approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

FDA approves Medtronic’s next-generation TAVR system with new frame design

The Evolut FX+ TAVR system includes an updated diamond-shaped frame, which was made four times larger than previous models to offer improved coronary access. It was also designed to provide more space for operators to guide and maneuver the catheter during procedures.

Heart attacks after TAVR: New AMI data ‘reassuring’ at first glance, but questions remain

Hoping to gain a better understanding of how TAVR may impact a patient’s long-term cardiovascular health, researchers explored data from more than 200,000 patients and shared their findings in JACC: Cardiovascular Interventions.

doctor comparing the costs of different medical treatments

TAVR is often more cost-effective than SAVR—but not always

Average lengths of stay and common complications are just some of the factors care teams should consider when evaluating the costs of aortic valve replacement. 

Displaying 121 - 128 of 2331

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup